Detalles de la búsqueda
1.
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Lancet
; 403(10432): 1164-1175, 2024 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402887
2.
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study.
Lancet Infect Dis
; 24(4): 417-426, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38237616
3.
Novel oral poliovirus vaccine type 2 is an important eradication tool, but reaching every last child remains vital.
Lancet Infect Dis
; 24(4): 337-339, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38246192
Resultados
1 -
3
de 3
1
Próxima >
>>